Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer

Perivascular cells (PC) were recently implied as regulators of metastasis and immune cell activity. Perivascular heterogeneity in clinical samples, and associations with other tumor features and outcome, remain largely unknown. Here we report a novel method for digital quantitative analyses of vessel characteristics and PC, which was applied to two collections of human metastatic colorectal cancer (mCRC). Initial analyses identified marker-defined subsets of PC, including cells expressing PDGFR-β or α-SMA or both markers. PC subsets were largely independently expressed in a manner unrelated to vessel density and size. Association studies implied specific oncogenic mutations in malignant cells as determinants of PC status. Semi-quantitative and digital-image-analyses-based scoring of the NORDIC-VII cohort identified significant associations between low expression of perivascular PDGFR-α and -β and shorter overall survival. Analyses of the SPCRC cohort confirmed these findings. Perivascular PDGFR-α and -β remained independent factors for survival in multivariate analyses. Overall, our study identified host vasculature and oncogenic status as determinants of tumor perivascular features. Perivascular PDGFR-α and -β were identified as novel independent markers predicting survival in mCRC. The novel methodology should be suitable for similar analyses in other tumor collections.

[1]  G. Wisman,et al.  Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival , 2016, Oncotarget.

[2]  Rakesh K. Jain,et al.  Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients , 2015, Proceedings of the National Academy of Sciences.

[3]  F. Pontén,et al.  High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort , 2015, PloS one.

[4]  Claudia Maggi,et al.  Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. , 2015, European journal of cancer.

[5]  R. Kalluri,et al.  Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. , 2015, Cell reports.

[6]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[7]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[8]  T. Wieland,et al.  RGS5 promotes arterial growth during arteriogenesis , 2014, EMBO molecular medicine.

[9]  Yihai Cao,et al.  Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis , 2013, Nature Communications.

[10]  R. Kalluri,et al.  Origin and function of myofibroblasts in kidney fibrosis , 2013, Nature Medicine.

[11]  B. Berghuis,et al.  Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma , 2013, Cancer.

[12]  G. Eberl,et al.  Lineage tracing and genetic ablation of ADAM12+ perivascular cells identify a major source of profibrotic cells during acute tissue injury , 2012, Nature Medicine.

[13]  H. Sorbye,et al.  Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[15]  A. Bardelli,et al.  Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia , 2011, Proceedings of the National Academy of Sciences.

[16]  D. Hanahan,et al.  Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. , 2011, Blood.

[17]  C. Betsholtz,et al.  Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. , 2011, Developmental cell.

[18]  O. Shupliakov,et al.  A Pericyte Origin of Spinal Cord Scar Tissue , 2011, Science.

[19]  P. Stattin,et al.  Stromal PDGFRβ Expression in Prostate Tumors and Non-Malignant Prostate Tissue Predicts Prostate Cancer Survival , 2010, PloS one.

[20]  D. Schadendorf,et al.  Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma , 2010, The Journal of experimental medicine.

[21]  H. Sorbye,et al.  Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients , 2009, Cancer.

[22]  C. Kuo,et al.  Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. , 2009, Cancer research.

[23]  D. Sargent,et al.  Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: a proposal for standardization of patient characteristic reporting and stratification. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  L. Ellis,et al.  Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. , 2007, The Journal of clinical investigation.

[25]  Ruud P. M. Dings,et al.  Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization , 2007, Clinical Cancer Research.

[26]  Bin Tean Teh,et al.  Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications , 2007, Clinical Cancer Research.

[27]  Holger Gerhardt,et al.  Pericytes limit tumor cell metastasis. , 2006, The Journal of clinical investigation.

[28]  T. Sjöblom,et al.  Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. , 2004, Cancer research.

[29]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  B R Johansson,et al.  Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. , 1997, Science.

[31]  A. McMahon,et al.  Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. , 2010, The American journal of pathology.

[32]  D. Brenner,et al.  Epithelial and Mesenchymal Cell Biology Pericytes and Perivascular Fibroblasts Are the Primary Source of Collagen-Producing Cells in Obstructive Fibrosis of the Kidney , 2010 .